S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

OTCMKTS:MATN - Mateon Therapeutics Stock Price, Forecast & News

$0.22
+0.01 (+4.76 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$0.19
Now: $0.22
$0.22
50-Day Range
$0.18
MA: $0.22
$0.27
52-Week Range
$0.05
Now: $0.22
$0.35
Volume15,317 shs
Average Volume42,917 shs
Market Capitalization$18.27 million
P/E RatioN/A
Dividend YieldN/A
Beta2.99
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc and changed its name to Mateon Therapeutics, Inc in June 2016. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MATN
Previous SymbolNASDAQ:MATN
CUSIPN/A
Phone650-635-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.01) per share

Profitability

Net Income$-2,740,000.00

Miscellaneous

Employees2
Market Cap$18.27 million
Next Earnings Date12/11/2019 (Estimated)
OptionableNot Optionable

Receive MATN News and Ratings via Email

Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter.


Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics Inc (OTCMKTS:MATN) issued its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.02). View Mateon Therapeutics' Earnings History.

When is Mateon Therapeutics' next earnings date?

Mateon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, December 11th 2019. View Earnings Estimates for Mateon Therapeutics.

What is the consensus analysts' recommendation for Mateon Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mateon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mateon Therapeutics.

What are Wall Street analysts saying about Mateon Therapeutics stock?

Here are some recent quotes from research analysts about Mateon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Mateon Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents for the treatment of cancer. Its product pipeline consists of VDAs-CA4P and OXi4503, which are in preclinical trail stage. Mateon Therapeutics, Inc., formerly known as OXiGENE, Inc., is based in SOUTH SAN FRANCISCO, United States. " (6/25/2019)
  • 2. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We are maintaining our Neutral rating on the shares and continue to not issue a price target currently. As mentioned above, we would look to potentially reassess our valuation following closing of the merger, additional due diligence on the new entity, and visibility into the ability to fund its programs. Underlying risk in the shares remain failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (4/22/2019)

Has Mateon Therapeutics been receiving favorable news coverage?

Media headlines about MATN stock have been trending positive on Wednesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Mateon Therapeutics earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View News Stories for Mateon Therapeutics.

Who are some of Mateon Therapeutics' key competitors?

What other stocks do shareholders of Mateon Therapeutics own?

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the folowing people:
  • Dr. William D. Schwieterman, Chairman, CEO & Pres (Age 61)
  • Mr. Matthew M. Loar, Chief Financial Officer (Age 56)
  • Ms. Shari Annes, Exec. Officer of Investor Relations
  • Dr. Yuval Binur, Exec. VP of Financial
  • Ms. Pamela Ha, Controller

How do I buy shares of Mateon Therapeutics?

Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of MATN stock can currently be purchased for approximately $0.22.

How big of a company is Mateon Therapeutics?

Mateon Therapeutics has a market capitalization of $18.27 million. Mateon Therapeutics employs 2 workers across the globe.View Additional Information About Mateon Therapeutics.

What is Mateon Therapeutics' official website?

The official website for Mateon Therapeutics is http://www.oncotelic.com/.

How can I contact Mateon Therapeutics?

Mateon Therapeutics' mailing address is 29397 AGOURA ROAD SUITE 107, AGOURA HILLS CA, 91301. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]


MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel